logo
Galderma Announces Departure of Its Chief Financial Officer

Galderma Announces Departure of Its Chief Financial Officer

Yahoo01-07-2025
Ad hoc announcement pursuant to Art. 53 LR
ZUG, Switzerland, July 01, 2025--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that Thomas Dittrich, Chief Financial Officer, will be leaving the company to pursue another senior executive opportunity outside the organization.
"We thank Thomas for his financial leadership and many contributions during his time at Galderma. He played a key role in establishing the financial discipline, operational readiness, and strategic clarity that will continue to guide us forward. We wish him every success in his next role and remain focused on further accelerating Galderma's strong growth – from category leadership to becoming a true powerhouse in dermatology."
FLEMMING ØRNSKOV, M.D., MPH
CHIEF EXECUTIVE OFFICER
GALDERMA
Thomas Dittrich will remain with the company as Chief Financial Officer through Q2 2026 to ensure a seamless transition through the close of the 2025 fiscal year. A successor will be announced in due course.
"I want to thank Flemming, our Board of Directors, our investors, and all my colleagues at Galderma for their support throughout what has been the most impactful transformation and growth journey of my career. I leave holding Galderma in the highest regard, enormously proud of the strides we've made together, and equally excited about Galderma's continued growth momentum and long-term success."
THOMAS DITTRICH
CHIEF FINANCIAL OFFICER
GALDERMA
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
Forward-looking statements
Certain statements in this announcement are forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "plans", "targets", "aims", " believes", "expects", "anticipates", "intends", "estimates", "will", "may", "continues", "should" and similar expressions. These forward-looking statements reflect, at the time, Galderma's beliefs, intentions and current targets/ aims concerning, among other things, Galderma's results of operations, financial condition, industry, liquidity, prospects, growth and strategies and are subject to change. The estimated financial information is based on management's current expectations and is subject to change. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which Galderma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Galderma's markets, and other factors beyond the control of Galderma). Neither Galderma nor any of their respective shareholders (as applicable), directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this announcement. Statements contained in this announcement regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. Some of the information presented herein is based on statements by third parties, and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, reasonableness, accuracy, completeness or correctness of this information or any other information or opinions contained herein, for any purpose whatsoever. Except as required by applicable law, Galderma has no intention or obligation to update, keep updated or revise this announcement or any parts thereof.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250630779859/en/
Contacts
For further information:
Christian Marcoux, M.Sc.Chief Communications Officerchristian.marcoux@galderma.com +41 76 315 26 50
Richard HarbinsonCorporate Communications Directorrichard.harbinson@galderma.com +41 76 210 60 62
Emil IvanovHead of Strategy, Investor Relations, and ESGemil.ivanov@galderma.com +41 21 642 78 12
Jessica CohenInvestor Relations and Strategy Directorjessica.cohen@galderma.com +41 21 642 76 43
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Moderna Cuts Forecast, Stock Wobbles Despite Beat
Moderna Cuts Forecast, Stock Wobbles Despite Beat

Yahoo

time8 minutes ago

  • Yahoo

Moderna Cuts Forecast, Stock Wobbles Despite Beat

Moderna's (NASDAQ:MRNA) quarter was okay on the numbers, but the stock slid because the company pulled back its full-year revenue outlook after delaying some U.K. vaccine shipments into early 2026. Q2 revenue was $142Million, down 41% from a year ago, with COVID shot sales at $114Million and its RSV vaccine barely registering. That pushed the 2025 revenue range to $1.5Billion$2.2Billion, about $300Million less than before. Warning! GuruFocus has detected 2 Warning Sign with MRNA. The good part is they've been cutting costs aggressively. OpEx is now guided to $5.9Billion$6.1Billion roughly $400Million lighter than prior expectationsand that helped trim the loss to about $800Million. Moderna still has a strong cash cushion: $7.5Billion at the end of June and roughly $6Billion expected at year-end, so the balance sheet isn't stressed. The delayed shipments rattled sentiment, but the company isn't burning cash. Now it comes down to executionU.K. deliveries must land as rescheduled and new revenue drivers need to show up before investors lose patience. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Liverpool ENTER midfielder transfer talks
Liverpool ENTER midfielder transfer talks

Yahoo

time8 minutes ago

  • Yahoo

Liverpool ENTER midfielder transfer talks

Liverpool have entered talks over a potential £15m transfer. As much as Richard Hughes will be honing on on new arrivals at the moment with the focus very much on Alexander Isak, and bringing in a new centre-back, there are still going to be some departures at the club as well. 🔴 Shop the LFC 2025/26 adidas home range from 9am TODAY Shop the LFC Store LFC x adidas Shop the away range TODAY LFC x adidas Shop the home range today! LFC x adidas Shop the goalkeeper range today LFC x adidas Shop the new adidas range today! There remains question marks over the future of Harvey Elliott, Federico Chiesa and Kostas Tsimikas. Meanwhile, at this point who knows what fate Darwin Nunez holds. These transfer deals are going to be crucial for Liverpool in order to balance the books. The Reds have spent a lot of money this summer but they also stand to recoup the vast majority of what they have spent through sales. Elliott in particular is going to command a significant fee. Meanwhile, Nunez, if Liverpool can find the right suitor, won't be leaving on the cheap either. And the Reds have also entered talks to complete a deal that would count as 'pure profit' when it comes to the Premier League's Profit and Sustainability Rules (PSR). 🔴 Shop the LFC 2025/26 adidas away range from 9am TODAY According to Sky Sports News, Liverpool are in talks with Lyon to sell Tyler Morton for what is expected to be a £15m transfer. Morton is an academy graduate, which means Liverpool could count the entire sale as a profit, considering he has been at the club from a young age. The 22-year-old has been on several loan spells over the course of his career and of course caught the eye in the Reds' first team as well. His best performance came against AC Milan in the Champions League at the San Siro in a game where Morton really emerged as a top-prospect. Since then, he has always stood-out for his excellent technical ability and his reading of the game. The only obstacle in his way in terms of making more regular first team minutes has been the level of players ahead of him in the pecking order. Right now Morton will know he is not guaranteed regular playing time but at his age he needs to be playing week in, week out in order to develop. Another loan to the Championship is probably not the right move for him either, having been at Blackburn Rovers and Hull City. This move to Lyon could be an excellent one. He'd be playing in a top five European league, at one of the best teams in that league. On top of that, Morton will be able to play in Europe as well, with Lyon having qualified for the Europa League. Another interesting caveat in these talks is that Liverpool are known for their admiration of Malick Fofana. So, perhaps letting Morton go to Lyon could open up a level of communication between the two sides that may ultimately see the French team return the favour for Fofana. It's definitely something to keep an eye on.

Fabrizio Romano confirms Liverpool in discussions about new forward
Fabrizio Romano confirms Liverpool in discussions about new forward

Yahoo

time8 minutes ago

  • Yahoo

Fabrizio Romano confirms Liverpool in discussions about new forward

Liverpool are busy trying to add Alexander Isak to their already star-studded squad. It's been a transfer window like no other for the Reds - with £260m-worth of talent already brought in. Florian Wirtz, Hugo Ekitike, Milos Kerkez, Jeremie Frimpong and Giorgi Mamardashvili have all arrived at Anfield. And Isak would top the lot - ANOTHER British record signing following the potential £116m acquisition of Wirtz from Bayer Leverkusen. 🚨2025/26 LFC x adidas range🚨 LFC x adidas Shop the home range today! LFC x adidas Shop the goalkeeper range today LFC x adidas Shop the new adidas range today! We've also seen the club conduct plenty of outgoing business. Luis Diaz, Jarell Quansah, Caoimhin Kelleher, Trent Alexander-Arnold and Nat Phillips have all departed. More exits are expected - with Darwin Nunez, Harvey Elliott, Tyler Morton, Federico Chiesa and Ben Doak among those listed for sale. How will Liverpool replace Diaz? The loss of Diaz has fuelled speculation that Richard Hughes could move in the market for a like-for-like replacement. Cody Gakpo is a capable left-wing performer - while others such as Rio Ngumoha, Wirtz and Ekitike can also take on responsibility in that sector. But having banked £65m for Diaz, Liverpool may well be active for a left winger. To that extent the club have been seriously linked with Malick Fofana from Lyon. Fofana is Lyon's prize asset The French Ligue 1 side are facing some severe financial headwinds and require sales this summer. Fofana is regarded as their most bankable asset - worth around €50m to €60m - and has attracted plenty of attention in the Premier League. Everton have been suggested as strong suitors but if Liverpool come calling then surely the Belgian will be attracted to Anfield instead. © IMAGO - Malick Fofana Liverpol

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store